Descending Pain Pathway in Opioid Functions
===========================================

Opioids are widely used pain therapeutics; however, the development of tolerance limits the long-term use of opioids due to the need for dose escalation over time in order to maintain analgesia. While there are four main types of opioid receptors, most pain therapeutics, including morphine, methadone, fentanyl, and oxycodone, target the mu opioid receptor (MOPr). The MOPr is a G-protein coupled receptor that couples to inhibitory heterotrimeric G-proteins (G~i/o~) producing subsequent intracellular signaling and ion conductance ([@B26]; [@B24]). MOPr expression within the descending pain modulatory pathway, which includes the ventrolateral periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and the dorsal horn (DH) of the spinal cord, contribute to opioid-induced antinociception and the development of opioid tolerance ([@B18]; [@B17]; [@B78]; [@B55]; [@B4]).

GABAergic neurons within the PAG are a critical site of action by opioids. Under normal conditions, these neurons have tonic activity (Figure [1](#F1){ref-type="fig"}, naive); however, upon binding of opioids to MOPr, the activity of these neurons is decreased, disinhibiting PAG projections to the RVM (Figure [1](#F1){ref-type="fig"}, Acute Morphine) ([@B75]; [@B80]; [@B2]). *In vitro* electrophysiology studies have shown that opioids reduce the frequency of spontaneous mIPSCs in PAG ([@B80]; [@B2]), which indicates a reduction in the probability of GABA release. This is also supported by *in vivo* studies. Microinjection of bicuculline (GABA~A~ agonist) into the PAG produces antinociception, which suggests that GABA is being tonically released ([@B2]). Furthermore, microdialysis in the PAG reveals a reduction in extracellular GABA following administration of morphine ([@B75]).

![The effects of morphine on neuronal transmission in the descending pain pathway. In the **naïve state**, GABAergic interneurons in the periaqueductal gray (PAG) fire tonically, thereby producing a steady release of GABA and inhibition of PAG output neurons. Upon administration of **acute morphine**, postsynaptic mu opioid receptor (MOPr) activate GIRK channels via Gα proteins resulting in K+ release and hyperpolarization of the neuron. Additionally, MOPr activate G~i/o~ proteins, which result in the inhibition of adenylyl cyclase (AC) and decrease cAMP production. Morphine binding of presynaptic MOPr inhibits voltage dependent calcium (Ca^2+^) conductances via Gβγ proteins and activated voltage dependent potassium conductances (Kv) via Phospholipase A (PLA). Overall, these two mechanisms block release of the neurotransmitter GABA, therefore suppressing inhibition, increasing output, of the PAG neurons projecting to the rostral ventromedial medulla (RVM). Acute morphine treatment also activates toll-like receptor 4 (TLR4) receptors on astrocytes and microglia in the PAG inducing several signaling cascades.](fnins-12-00886-g001){#F1}

Opioids activate different signaling cascades depending on whether the MOPr is expressed at pre- or post- synaptic sites. Opioid binding to postsynaptic MOPr results in the activation of a G-protein inwardly rectifying potassium channels (GIRK) that hyperpolarize GABAergic neurons in the PAG producing an overall decrease in GABAergic neuron activity (Figure [1](#F1){ref-type="fig"}; Acute Moprhine) ([@B61]; [@B63]). Alternatively, when MOPr are expressed at presynaptic sites they produce an inhibition of voltage gated calcium channels and voltage gated potassium channels (Kv) resulting in the inhibition of GABA release (Figure [1](#F1){ref-type="fig"}; Acute Morphine) ([@B85]; [@B80]; [@B12]; [@B86]). Overall, the combined action of MOPr binding by opioids is a decrease in GABAergic neuronal activity, and therefore an increase in output from the PAG to the RVM (Figure [1](#F1){ref-type="fig"}; [@B51]; [@B14]; [@B38]; [@B62]). Recent studies support the hypothesis that this increase in PAG output to the RVM is a main contributor to the opioid-induced antinociception by demonstrating that selective inhibition of GABAergic neurons or activation of glutamatergic output neurons in the PAG mimics the antinociceptive effects of opioids ([@B70]). In summary, these findings support the notion that analgesia is produced by disinhibition of excitatory outputs from the PAG.

The overall effect of MOPr activation in the PAG is an increase in output to the two distinct cell types within the RVM: off-cells and on-cells ([@B20]; [@B21]). The activity of off-cells pauses just prior to the response to a painful stimulus, while the activity of on-cells increases during this response, and both of these activities are blocked during the administration of opioids. There is conflicting evidence regarding the excitatory versus inhibitory nature of the PAG projections to the on- and off-cells in the RVM. Studies in GAD67-GFP mice, a marker for GABAergic neurons, show that retrogradely labeled neurons from the RVM do no co-localize with GAD67 in the PAG ([@B64]), indicating that the PAG to RVM projection is glutamatergic. In contrast, studies in rats demonstrate that PAG to RVM projections are a mix of GABAergic and glutamatergic neurons ([@B57]). Furthermore, these studies demonstrate that GABAergic neurons project from PAG and target on-cells and glutamatergic neurons project from the PAG and target off-cells ([@B57]). Despite these differences, both studies support the notion that opioids inhibit GABA release from interneurons in the PAG, which disinhibit (i.e., excite) glutamate projections to off-cells. Given that the off-cells in the RVM are GABAergic, they subsequently inhibit pain responses in the DH ([@B20]; [@B51]; [@B57]). Overall, these studies support the concept that opioid-induced antinociception is mediated by direct excitation of off-cells and subsequent inhibition of pain in the spinal cord.

At each level of this pathway, a myriad of cellular effects drives the physiological changes mentioned above, and are highly correlated with the development of opioid tolerance. One of the most studied mechanisms involves regulation and signaling at the MOPr. Current research demonstrates that while MOPr is a key player in the development of antinociceptive tolerance, mechanisms beyond simple receptor desensitization, including alterations in neurotransmission and β-arrestin dependent signaling, are also critical. Furthermore, MOPr expression in non-neuronal cells, specifically on microglia and astrocytes within the spinal cord, and more recently within the PAG, greatly contributes to the development of opioid tolerance.

Opioid Tolerance and Neurotransmission in the Descending Pain Pathway
=====================================================================

Evidence suggests that tolerance is due to changes in the properties of GABAergic neurons in the PAG ([@B54]). First of all, while microinjection of morphine into the PAG or RVM produces antinociception, repeated microinjection into the PAG and not the RVM results in tolerance ([@B53]; [@B8]). Secondly, inhibition of MOPrs within the PAG blocks tolerance to systemic morphine ([@B42]). Furthermore, inactivation of RVM by a GABA agonist during direct administration of morphine into the PAG still leads to tolerance development ([@B42]). Therefore, MOPr within the PAG are necessary and sufficient in the development of opioid tolerance.

However, the development of tolerance within the PAG produces downstream effects along the descending pain pathway. This is evidenced by the fact that direct injection of morphine into the PAG affects RVM signaling, suggesting that their activity is in fact coupled ([@B78]). While acute administration of opioids into the PAG disrupts the activity of on- and off- cells in response to painful stimuli, these cells respond normally following chronic infusion that is associated with tolerance ([@B43]). Another side effect of chronic morphine treatment is hyperalgesia, or the increased sensitivity to pain following chronic morphine treatment. One theory is that hyperalgesia may manifest as opioid-induced tolerance since increased sensitivity to pain would counteract the pain-relieving effects of opioids. Some studies suggest that increased activation of the descending pain pathway by chronic morphine produces neuroadaptations with in the RVM that result in hyperalgesia ([@B79]). In support of this, one study demonstrated that chronic morphine produced an increase in the number of active on-cells, likely increasing sensitivity to noxious stimuli ([@B50]), which may be responsible for morphine-induced hyperalgesia. While RVM plays a role in opioid-induced tolerance, direct injections into the RVM leads to a lesser development of tolerance compared to PAG administration ([@B53]), indicating that activation of the entire descending pain circuit is essential.

The neurophysiological mechanisms of tolerance in the PAG are mediated by MOPr uncoupling from downstream G-protein mediated signaling (Figure [2](#F2){ref-type="fig"}). One key study demonstrated that chronic morphine decreases opioid-mediated GIRK currents in the PAG ([@B1]), supporting the notion that morphine tolerance is associated with uncoupling of G-protein mediated signaling. Since GIRK channels regulate neuronal excitability, this mechanism would result in a reduction in the ability of MOPr activation to suppress GABAergic neuron activity. Additionally, morphine tolerance is also associated with decreased efficacy of other MOPr agonists ability to reduce voltage gated calcium currents in the PAG ([@B1]). The net effect of the uncoupling of MOPr activation from voltage gated calcium channels would be the attenuation of MOPr mediated inhibition of GABA release. However, the precise mechanisms underlying MOPr uncoupling from voltage gated calcium channels are complex, as cellular tolerance associated with this effect was not observed in β-arrestin two knockout mice ([@B11]), suggesting that β-arrestin two also plays a role in this interaction.

![Effects of repeated morphine treatment on glial and neuronal signaling in the PAG. Chronic morphine treatment induces several side effects that block opioid-induced decreases in GABAergic interneuron activity at the neuronal level, postsynaptically. This includes the uncoupling of MOPr from G-protein mediated effects on GIRK channels and AC. This results in an upregulation of cAMP. Uncoupling also occurs in the presynaptic region, blocking the Gβγ mediated inhibition of calcium channels and PLA mediated activation of Kv channels. In this state, binding of opioids to MOPr no longer results in suppression of GABA release. At the level of glial signaling, upon repeated treatment with morphine, there is a rapid upregulation of TLR4 on astrocytes and microglia within the PAG, resulting in an increase in excitatory cytokine release, as well as a switch from G~i/o~ to G~s~ coupling at MOPr, resulting in an overall increase in excitatory tone that is correlated with opioid tolerance.](fnins-12-00886-g002){#F2}

GABA release is also regulated by signaling through phospholipase A2-mediated activation of voltage gated potassium channels (Figure [1](#F1){ref-type="fig"}; [@B87]; [@B80]). This signaling pathway is differentially affected by morphine tolerance versus withdrawal. Morphine tolerance is associated with a decrease in opioid-mediated inhibition of GABA release (Figure [2](#F2){ref-type="fig"}) that is not a result of MOPr desensitization ([@B22]). However, during naloxone-precipitated withdrawal following chronic morphine, GABA release is enhanced via an increase in adenylyl cyclase (AC) signaling ([@B71]; [@B36]; [@B29]). These two outcomes may be related as studies have demonstrated that inhibition of AC in the PAG prevents the development and expression of morphine tolerance ([@B2]). Moreover, AC activation is sufficient to increase GABA release from PAG neurons ([@B2]).

Intracellular Signaling Changes in the PAG-RVM-DH Pathway in Opioid Tolerance
=============================================================================

Direct activation of the MOPr results in the Gα subunit-mediated inhibition of the AC-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) pathway (Figure [1](#F1){ref-type="fig"}; [@B71]; [@B28]; [@B31]). However, opioid binding activates other signaling proteins, such as protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) via β-arrestin pathways, which are independent of G-protein signaling. As mentioned previously, downstream of G-protein mediated signaling, there is an inhibition of calcium channels and activation of potassium channels that leads to hyperpolarization and a reduction in neurotransmitter release in the PAG that produces antinociception ([@B5]; [@B37]; [@B77]). Chronic morphine produces adaptations that contribute to opioid-tolerance within all these downstream signaling pathways.

Long-term opioid treatment leads to adaptations in many signaling proteins within the PAG-RVM-DH pathway, which have been proposed as mechanisms of opioid tolerance. In contrast to the acute inhibitory effect of opioids on cAMP production, chronic morphine treatment upregulates cAMP (Figure [2](#F2){ref-type="fig"}; [@B28]; [@B24]). It has been proposed that this upregulation in cAMP is caused by compensatory changes in intracellular signaling, or an uncoupling of G~i/o~-proteins from the receptor and a switch to coupling with G~s~-proteins ([@B24]). Very few *in vivo* studies have evaluated the role of the AC pathway in morphine tolerance, but inhibition of the AC pathway, via either intracerebroventricular (ICV) or intra-PAG injection, during morphine pretreatment has been shown to block the development of morphine tolerance ([@B72]; [@B23]; [@B2]). In the DH, administration of morphine results in no change or even an increase in MOPr expression, but a significant down-regulation of the G-protein activation in the DH, as measured by \[^35^S\]-GTPyS ([@B48]; [@B68]). The loss of G-protein signaling is likely a switch in MOPr G-protein coupling, from G~i/o~ to G~s~ coupling ([@B24]). Recently, adrenomedullin, a pronociceptive peptide from the CGRP family, has been implicated in mediating this G-protein switch in the DH. Following chronic morphine, adrenomedullin is significantly upregulated in the DH and dorsal root ganglia, and inhibition of its receptor prevents or reverses morphine tolerance and blocks the MOPr G~i/o~ to G~s~ switch in coupling ([@B82]).

Behavioral studies suggest that the mechanisms underlying tolerance are dependent on the specific MOPr agonist being studied. Some agonists, such as morphine, do not readily recruit β-arrestin or internalize the receptor, as compared to high efficacy agonists, such as DAMGO or fentanyl, which readily do both. This difference in signaling suggests differences in tolerance mechanisms, where morphine-mediated tolerance utilizes a G-protein dependent mechanism, and other MOPr agonists, such as DAMGO or fentanyl, use a β-arrestin dependent mechanism ([@B33]; [@B49]; [@B2], [@B3]; [@B56]). For example, inhibition of ERK1/2 within the PAG during the development of tolerance enhances morphine tolerance ([@B47]), but reduces tolerance to DAMGO and has no effect on fentanyl tolerance ([@B3]). Furthermore, inhibition of the G-protein dependent pathway (i.e., c-Jun N-terminal kinase) blocks development of tolerance to morphine, but not fentanyl. However, inhibition of β-arrestin dependent signaling (i.e., G protein-coupled receptor kinase) blocks expression of fentanyl tolerance ([@B56]).

Neuropeptides within the descending pain pathway have also been shown to regulate opioid tolerance. One such neuropeptide, cholecystokinin (CCK), is particularly enriched in supraspinal midbrain regions known to regulate spinal nociception ([@B40]). There is evidence that CCK acting within the PAG-RVM-DH pathway regulates morphine tolerance ([@B89]; [@B76]). A CCK receptor antagonist, directly injected into the PAG, is able to block morphine tolerance ([@B89]). In the RVM, injection of CCK blocks opioid activation of off-cells that mediate descending antinociception, resulting in a blockade of the analgesic effects of morphine ([@B91]; [@B76]).

*N*-methyl D-aspartate receptors (NMDArs) have been heavily implicated in the development of both spinal-mediated hyperalgesia and opioid tolerance. NMDAr antagonists or the targeted disruption of the NR2 subunits, NR2a and NR2b, attenuates opioid tolerance ([@B65]; [@B92]). Deletion of PSD-93, the anchoring protein for NR2a and NR2b in the synapse, leads to a DH site-specific down-regulation of both subunits from the plasma membrane into the cytosolic compartment, and a reduction in the development of morphine tolerance ([@B45]). This is a region-specific effect, as other portions of the descending pain pathway did not see changes in the NR2 subunit localization ([@B41]). Interestingly, NMDArs in the PAG have not been implicated in tolerance ([@B52]).

A few other main signaling targets have been implicated in DH-mediated opioid tolerance, as well. Mammalian target of rapamycin (mTOR) is found to be upregulated following repeated intrathecal morphine administration, and this effect is mediated by activation of PI3K/AKT following MOPr activation ([@B90]). Administration of mTOR inhibitors is able to both prevent and reverse morphine tolerance ([@B91], [@B90]; [@B39]; [@B10]). Calcium/calmodulin-dependent protein kinase IIα has also been implicated in the development of tolerance ([@B6]). It has been shown to colocalize with MOPr, in the DH specifically, following opioid administration, possibly resulting in increased MOPr phosphorylation and desensitization ([@B6]).

Impact of Opioid-Induced Neuroinflammation on the Development of Tolerance
==========================================================================

Over the past few decades, researchers have discovered that opioids are potent activators of immune cells within the CNS, and this inflammation is a strong contributor to the development of opioid tolerance ([@B25]; [@B7]). Specifically, repeated administration of opioids, which leads to activation of glia within the PAG and spinal cord of the descending pain pathway, results in alterations in both intracellular signaling cascades and signaling properties of neurons. Furthermore, microglial inhibitors have been shown to attenuate morphine-induced tolerance ([@B73]; [@B66], [@B67]; [@B13]; [@B16]; [@B30]). Though the precise mechanisms that underlie these changes are only beginning to be uncovered, a few notable pathways have emerged that are likely significant contributors to the development of opioid tolerance.

One prominent pro-inflammatory signaling cascade that has been implicated in opioid tolerance involves the immune receptor, toll-like receptor 4 (TLR4, Figure [2](#F2){ref-type="fig"}). Upon agonist binding to TRL4, sphingomyelinase produces ceramide, which allows for interaction of the receptor with its co-activators myeloid differentiation factor-2 (MD-2) and CD14, resulting in subsequent activation of 3 parallel pathways: the p38-MAPK pathway, the PI3K/AKT pathway (cell survival/apoptosis), and the NFκB pathway (proinflammatory cytokine release) ([@B69]; [@B84]; [@B59]; [@B16]). In the spinal cord, TLR4 is primarily expressed on microglial cells and is shown to be upregulated (Figure [2](#F2){ref-type="fig"}) along with its cofactor MD-2 following morphine treatment ([@B83]), and activation of TLR4 signaling can induce "naïve tolerance" to opioids ([@B16]; [@B27]). Furthermore, inhibition of TLR4, co-activators MD-2 or CD14, or inhibition of ceramide biosynthesis, leads to attenuation of morphine tolerance, as well as decreased microglial activation, suggesting a prominent role for the TLR4 pathway in the development of opioid tolerance, at the level of the spinal cord ([@B60]; [@B35], [@B34]; [@B58]; [@B76]).

Interestingly, it is also thought that TLR4 is directly activated by opioids (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}; [@B34]; [@B83]; [@B27]), and, perhaps more importantly, the accessory protein MD-2 is able to non-stereoselectively bind opioids and signal through TRL4 ([@B27]). Since the classic opioid receptors only bind the (−)-opioid isomer, the (+)-opioid isomer antagonists could be used to block TLR4-mediated microglial activation and pro-inflammatory cytokine production. In fact, studies have demonstrated that (+)-naloxone is able to attenuate morphine-induced analgesia, specifically at the level of the spinal cord ([@B35]; [@B44]). This non-stereoselectivity at the TLR4 receptor complex could potentially be leveraged for the enhancement of the therapeutic efficacy of opioids, including enhancing analgesic effects and reducing tolerance.

How does the activation of glial cells lead to alterations in neuronal signaling? One possibility is through the alteration of neuronal excitability via increased release of glially-derived pro-inflammatory cytokines, including TNF (tumor necrosis factor) and IL-1β, which are known to increase neuronal AMPA and NMDA receptors, as well as down regulate GABA receptors ([@B81]; [@B74]). Within the PAG, repeated morphine administration results in an upregulation of TLR4, which subsequently leads to an increase in release of TNF and IL-1β ([@B16]; [@B15]). This upregulation is concurrent with a downregulation of astrocyte glutamate transporters GLT-1 and GLAST, which are responsible for synaptic glutamate uptake. The overall effect is an increase in neuronal excitability, thereby lowering the ability of opioids to hyperpolarize mu-containing GABAergic neurons (Figure [2](#F2){ref-type="fig"}). Within the PAG to RVM circuitry, this results in an inability for morphine to disinhibit output neurons to RVM ([@B16]; [@B15]).

Another potential point of cross talk is via purinergic receptors, specifically P2X4 and P2X7, which are primarily expressed on microglia. These receptors are also capable of upregulating pro-inflammatory cytokines, and blocking their activity in the spinal cord attenuates morphine tolerance ([@B32]; [@B93]; [@B88]). P2X4 activates the p38-MAPK pathway, resulting in the release of IL-1β, TNF-α, and BDNF, which, as mentioned above, are known to alter neuronal excitability and contribute to pain hypersensitivity, but no direct connection has been made to opioid tolerance ([@B19]; [@B27]; [@B76]). However, P2X7 mediated release of IL-18 from microglia induces activation of the IL-18 receptor on astrocytes, thereby increasing the release of D-serine, which is able to activate NMDA receptors in neurons. Activation of both receptors is able to alter glial activation and neuronal excitability, suggesting a complicated crosstalk between cell types in the spinal cord that is correlated with morphine tolerance ([@B9]).

Conclusion
==========

The descending pain pathway is a critical modulator of nociception and plays an important role in mediating endogenous and exogenous opioid-induced analgesia. Because of this, it is highly implicated in allostatic cellular and molecular changes following repeated opioid use that lead to the development of tolerance. While this review has touched on a number of those changes at each level of the descending pain pathway, including desensitization of MOPr, altered cellular excitability and signaling, and induction of immune-competent cells, we do not yet have a complete understanding of all the factors that might be contributing to opioid tolerance.

Much of the literature on opioid tolerance has focused the effects of morphine on this system. Future research must expand to include other commonly used opioids, especially in light of the increasing use of oxycodone and fentanyl, as each of these has widely different pharmacokinetic and signaling profiles, and may have differential effects on each level of the PAG-RVM-DH pathway. Indeed, studies looking at cross-tolerance between opioid analgesics suggest that differences in the distribution of the drug within the pain pathway may be differentially contributing to the development of tolerance. Furthermore, the cellular signaling pathways initiated within these spinal and supraspinal regions following administration of different opioids are known to vary.

Finally, the research design of the studies related to opioids and tolerance has varied widely in terms of not only the drugs used, but also routes of administration, length of exposure, and use of biological systems. Also, the majority of studies on opioid tolerance have focused on males and have largely excluded females. Given that males show greater morphine potency, tolerance, and activation of neurons from PAG to RVM following morphine, as compared to females ([@B46]), it is imperative to further explore these differences. Overall, these variations in research design have resulted in a myriad of observed cellular changes that correlate with tolerance, but with no definite conclusions or unifying theories of tolerance. While no one specific etiology may exist, future researchers must be careful in designing these studies, in order to make meaningful conclusions regarding the cellular impact of opioids in the development of tolerance.
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